Novel short peptides isolated from phage display library inhibit vascular endothelial growth factor activity

Signal transduction through the vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR) pathway has a pivotal importance in angiogenesis, and has therefore become a prime target in antitumor therapy. In search for peptides antagonizing VEGF binding to its receptors, we screened a random heptamer library displayed on phage for peptides that bind the whole VEGF165 molecule and inhibit VEGF dependent human umbilical vein endothelial cell (HUVEC) proliferation. Two selected peptides with sequences WHLPFKC and WHKPFRF were synthesized. Biacore and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis indicated that these peptides bind the VEGF homodimer in a concentration-dependent manner, with micromolar affinity, and with a 2:1 peptide: VEGF stoichiometry. They inhibited HUVEC proliferation in vitro by 77 and 55%, respectively. Taken together, our results indicate that these peptides could be potent inhibitors of angiogenesis. Furthermore, we show that the peptide-VEGF binding properties can be quantified, a prerequisite for the further optimization of binders.

[1]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[2]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[3]  R. Ladner,et al.  Phage display-derived peptides as therapeutic alternatives to antibodies. , 2004, Drug discovery today.

[4]  G. P. Smith,et al.  Libraries of peptides and proteins displayed on filamentous phage. , 1993, Methods in enzymology.

[5]  Li Xiaoying,et al.  A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor* , 2002, The Journal of Biological Chemistry.

[6]  J. Arends,et al.  Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. , 1999, European journal of biochemistry.

[7]  K. Alitalo,et al.  The biology of vascular endothelial growth factors. , 2005, Cardiovascular research.

[8]  Hajime Takashima,et al.  A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155. , 2003, Molecular cancer therapeutics.

[9]  J. Schneider-Mergener,et al.  Vascular Endothelial Growth Factor (VEGF) Receptor II-derived Peptides Inhibit VEGF* , 1999, The Journal of Biological Chemistry.

[10]  B. Monk,et al.  Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. , 2005, Gynecologic oncology.

[11]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[12]  A G Cochran,et al.  Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. , 1998, Biochemistry.

[13]  J. Arends,et al.  Somatostatin displayed on filamentous phage as a receptor‐specific agonist , 1998, British journal of pharmacology.

[14]  T. Aizawa,et al.  Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. , 2005, Journal of biotechnology.

[15]  D. Hicklin,et al.  Monoclonal antibody strategies to block angiogenesis. , 2001, Drug discovery today.

[16]  A. Bikfalvi,et al.  Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. , 2002, Trends in pharmacological sciences.

[17]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[18]  N. Oku,et al.  Suppression of tumor growth by novel peptides homing to tumor‐derived new blood vessels , 2002, FEBS letters.

[19]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[20]  T. Maciag,et al.  An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[22]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[23]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[24]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[25]  Sunjoo Jeong,et al.  Inhibition of the angiogenesis by the MCP‐1 (monocyte chemoattractant protein‐1) binding peptide , 2005, FEBS letters.

[26]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.

[27]  Lin Meng,et al.  Suppression of tumor growth and metastasis by a VEGFR‐1 antagonizing peptide identified from a phage display library , 2004, International journal of cancer.

[28]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.